Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy: A Critical Appraisal of the MENTOR Study

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HA0001-000

Membranous nephropathy is an autoimmune disease that commonly presents as nephrotic syndrome. The current guideline recommends treating this condition with cyclophosphamide and corticosteroids. Alternatively, cyclosporine or tacrolimus may be used.

The MENTOR study, published in July 2019, compared rituximab with cyclosporine in inducing and maintaining the remission of proteinuria in patients with primary membranous nephropathy. The purpose of this Canada's Drug Agency report is to describe the internal and external validity of the MENTOR study.

Files

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy: A Critical Appraisal of the MENTOR Study Technology Review February 4, 2020 View PDF
Last Updated : January 23, 2020